Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6902686 | 0.83 | ALDH1A1 (0.48) | ALDH1A1KMT2ATDP1MEN1CYP2A6 | |
| SCHEMBL96214 | 0.83 | ALDH1A1 (1.00) | ALDH1A1KMT2ATDP1MEN1HSP90AA1 | |
| SCHEMBL28806185 | 0.80 | ALDH1A1 (0.94) | ALDH1A1KMT2ATDP1MEN1HSP90AA1 | |
| SCHEMBL3784795 | 0.74 | TDP1 (0.73) | ALDH1A1KMT2ATDP1MEN1HSP90AA1 | |
| SCHEMBL5153352 | 0.74 | MEN1 (0.48) | ALDH1A1KMT2ATDP1MEN1CYP2A6 | |
| SCHEMBL611923 | 0.73 | ALDH1A1 (0.70) | ALDH1A1KMT2ATDP1MEN1HSP90AA1 | |
| SCHEMBL1571095 | 0.73 | ALDH1A1 (0.70) | ALDH1A1KMT2ATDP1MEN1HSP90AA1 | |
| SCHEMBL13456108 | 0.73 | TDP1 (0.39) | ALDH1A1KMT2ATDP1MEN1SMN1; SMN2 | |
| SCHEMBL910073 | 0.73 | ALDH1A1 (0.70) | ALDH1A1KMT2ATDP1MEN1HSP90AA1 | |
| SCHEMBL3685875 | 0.73 | ERN1 (0.45) | ALDH1A1KMT2ATDP1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225618-A1 | IDO Inhibitors | MAUTINO MARIO (US) | 2019-07-25 | — | — | US | disclosed |
| US-10233190-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3348558-A1 | COMPOSITIONS COMPRISING FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | Newlink Genetics Corporation (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180118753-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-9850248-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160362412-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2016-12-15 | — | — | US | disclosed |
| US-9388191-B2 | Fused imidazole derivatives useful as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2016-07-12 | — | — | US | disclosed |
| EP-3018132-A1 | FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | Newlink Genetics Corporation (US) | 2016-05-11 | — | — | EP | disclosed |
| US-9260434-B2 | Fused imidazole derivatives useful as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2697227-B1 | FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | NEWLINK GENETICS CORP (US) | 2016-02-03 | — | — | EP | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| CN-101374516-A | Use of substituted 2-imidazole of imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362412-A1 | IDO Inhibitors | IDO1, IDO2, INMT | ALDH1A1 1338/4885KMT2A 356/4885TDP1 1271/4885 |
| US-20180118753-A1 | IDO Inhibitors | IDO1, IDO2, INMT | ALDH1A1 1338/4885KMT2A 356/4885TDP1 1271/4885 |
| US-20190225618-A1 | IDO Inhibitors | IDO1, IDO2, INMT | ALDH1A1 1297/4885KMT2A 357/4885TDP1 1237/4885 |
| US-10233190-B2 | IDO inhibitors | IDO1, IDO2, INMT | ALDH1A1 1338/4885KMT2A 356/4885TDP1 1271/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | ALDH1A1 412/4885KMT2A 805/4885TDP1 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.